ACQUISITION OF SUBSIDIARIES (Details Narrative) |
12 Months Ended | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jan. 13, 2026
EUR (€)
shares
|
Jan. 07, 2026
shares
|
Oct. 03, 2025
shares
|
Mar. 31, 2026
USD ($)
shares
|
Mar. 31, 2025
USD ($)
shares
|
Mar. 31, 2024
USD ($)
|
Mar. 27, 2026
shares
|
Sep. 08, 2025
shares
|
Jul. 22, 2025
shares
|
Mar. 10, 2025
USD ($)
|
Jan. 27, 2025
USD ($)
|
Jan. 23, 2025
shares
|
Jan. 21, 2025
shares
|
Dec. 20, 2024
shares
|
Jul. 26, 2024
USD ($)
|
Jul. 15, 2024
shares
|
|
| IfrsStatementLineItems [Line Items] | ||||||||||||||||
| Post share consolidation, shares | 22,088,293 | |||||||||||||||
| Number of shares issued | 62,074 | 29,100,941 | 22,993,763 | 201,950,104 | 2,250,000 | 2,250,000 | 731,707 | 2,347,134 | ||||||||
| Loss for the year | $ | $ (31,146,283) | $ (5,212,879) | $ (4,871,387) | |||||||||||||
| Revenue for the year | $ | 3,615,748 | 2,040,602 | 1,299,538 | |||||||||||||
| Share Capital | $ | 11,641 | 1,150 | $ 13,000,000 | $ 130 | ||||||||||||
| Proceeds from ordinary shares | $ | $ 10,608,750 | |||||||||||||||
| Acquisition of plana earth gmbh shares [member] | ||||||||||||||||
| IfrsStatementLineItems [Line Items] | ||||||||||||||||
| Post share consolidation, shares | 840,040 | |||||||||||||||
| Purchase price were settled | 6,720,317 | |||||||||||||||
| Remedy project limited [member] | ||||||||||||||||
| IfrsStatementLineItems [Line Items] | ||||||||||||||||
| Post share consolidation, shares | 125,000 | 31,250 | ||||||||||||||
| Number of shares issued | 1,000,000 | 250,000 | ||||||||||||||
| Loss for the year | $ | 98,359 | |||||||||||||||
| Revenue for the year | $ | 33,663 | |||||||||||||||
| Consideration transferred | $ | 5,684,999 | |||||||||||||||
| Acquired interest percentage | 100.00% | |||||||||||||||
| Additional number of shares issued | 1,000,000 | 250,000 | ||||||||||||||
| Fair value of contingent arrangement | $ | ||||||||||||||||
| Remedy project limited [member] | Ordinary shares two [member] | ||||||||||||||||
| IfrsStatementLineItems [Line Items] | ||||||||||||||||
| Description of shares acquiree | 250,000 Ordinary Shares (Post Share Consolidation: 31,250 Ordinary Shares) – achieve an EBITDA target of $4.1m for the year ending March 31, 2028 | |||||||||||||||
| Remedy project limited [member] | Ordinary shares three [member] | ||||||||||||||||
| IfrsStatementLineItems [Line Items] | ||||||||||||||||
| Description of shares acquiree | 250,000 Ordinary Shares (Post Share Consolidation: 31,250 Ordinary Shares) – achieve an EBITDA target of $8.2 m for the year ending March 31, 2029 | |||||||||||||||
| Remedy project limited [member] | TRP earns out [member] | ||||||||||||||||
| IfrsStatementLineItems [Line Items] | ||||||||||||||||
| Additional number of shares issued | 500,000 | |||||||||||||||
| Plan A Earth gmbH [member] | ||||||||||||||||
| IfrsStatementLineItems [Line Items] | ||||||||||||||||
| Loss for the year | $ | $ 849,553 | |||||||||||||||
| Revenue for the year | $ | 582,390 | |||||||||||||||
| Consideration transferred | $ | $ 20,857,516 | |||||||||||||||
| Acquired interest percentage | 100.00% | |||||||||||||||
| Proceeds from ordinary shares | € | € 3 | |||||||||||||||
| Restrictions on transfer of consideration shares | The Ordinary Shares are subject to a lock-up as follows: (a) 25% released at 6 months after the closing date; (b) a further 25% released at 9 months after the closing date; (c) a further 25% released at 12 months after the closing date; and (d) the remaining 25% released at 15 months after the closing date. | |||||||||||||||
| Contingent consideration in business combination | subject to the achievement of the financial targets set forth below, the Sellers shall be entitled to a performance related earn out payment for fiscal years 2026 and 2027. An amount of €10 million shall be payable in Ordinary Shares, at a share price of $9.10 (Post Share Consolidation: share price of $72.80), if the fully paid annualized value of recurring revenue of planA (the “Paid ARR”) in the twelve months period ending on March 31, 2027 (the “FY 2026”) amounts to or exceeds €11.3 million (the “ARR Target 2026”). Twenty percent of any excess Paid ARR in FY 2026 shall be counted towards the ARR Target 2027 (the “excess FY 2026 ARR”), as defined below. An amount of €15 million (the “ARR Target 2027”) shall be payable in Ordinary Shares, at a share price of $9.10 (Post Share Consolidation: share price of $72.80), if the Paid ARR in the twelve months period ending on 31 March 2028 (the “FY 2027” and together with excess FY 2026 ARR) amounts to or exceeds €17 million. Management determined that the fair value of such contingent settlement amounted to $Nil as at the acquisition date and March 31, 2026. | |||||||||||||||
| Ordinary shares [member] | ||||||||||||||||
| IfrsStatementLineItems [Line Items] | ||||||||||||||||
| Number of shares issued | 6,869,960 | |||||||||||||||
| Share Capital | $ | $ 50,000 | |||||||||||||||
| Matter DKApS [member] | ||||||||||||||||
| IfrsStatementLineItems [Line Items] | ||||||||||||||||
| Percentage of ownership interest | 100.00% | 100.00% | ||||||||||||||
| Purchase consideration shares | 1,241,496 | |||||||||||||||
| Post share consolidation, shares | 155,187 | |||||||||||||||
| Number of shares issued | 1,055,272 | |||||||||||||||
| Post share consolidation shares issued upon closing of transaction | 131,909 | |||||||||||||||
| Shares issued balance | 186,224 | |||||||||||||||
| Post share consolidation shares issued after closing | 23,278 | |||||||||||||||
| Loss for the year | $ | $ 2,339,650 | |||||||||||||||
| Revenue for the year | $ | 569,375 | |||||||||||||||
| Share Capital | $ | $ 13,500,000 | |||||||||||||||
| Consideration transferred | $ | $ 20,500,000 | |||||||||||||||
| Description of impairment loss and recognition of goodwill | commercial valuation of the acquired cash-generating unit (CGU) remained supported at $13.5 million based on operational projections, the excess consideration value of $7.0 million (the difference between the accounting fair value of $20.5 million and the business valuation of $13.5 million) was determined to be unrecoverable through future cash flows. Accordingly, a impairment loss on goodwill of $7.0 million was recognized at the initial integration date and is included within the “other income, gains or losses” line item in the consolidated statement of profit or loss for the year ended March 31, 2026. | |||||||||||||||
| Discount rate | 16.90% | |||||||||||||||
| Matter DKApS [member] | Ordinary shares [member] | ||||||||||||||||
| IfrsStatementLineItems [Line Items] | ||||||||||||||||
| Purchase consideration shares | 62,074 | |||||||||||||||
| Post share consolidation, shares | 7,759 | |||||||||||||||
| Number of shares issued | 10,923,682 | |||||||||||||||